Table 2

Data set definitions and list of analyses

	24-Week placebo controlled period		All Bari-RA	Haematological extended set		JADV	Platelets extended set*	Baseline JADV, JADX	JADN
Data sets definition	Placebo-controlled periods through 24 weeks		All patients with RA with ≥1 dose of Bari	Placebo controlled periods and LTE, studies with LTE option only		Study-specific analyses	Placebo controlled periods and LTE	Study-specific analysis	Study-specific analyses
Treatment	Placebo, Bari 4 mg	Bari 2 mg	Bari 1, 2, 4, 5, 7, 8, 10 or 15 mg once daily or 2 mg two times per day	Placebo, Bari 4 mg	Bari 2 mg	Bari 4 mg	Bari 4 mg	NA	Placebo, Bari 2 mg, Bari 4 mg
Studies	JADA, JADC, JADN, JADV, JADW, JADX	JADA, JADN, JADW, JADX	JADA, JADB, JADC, JADN, JADV, JADW, JADX, JADZ and LTE	JADA, JADV, JADW, JADX and LTE	JADA, JADW, JADX and LTE	JADV	JADA, JADC, JADN, JADV, JADW, JADX, JADZ and LTE	JADV, JADX	JADN
Censoring	At rescue		None	At rescue or dose change		At rescue	At rescue or dose change	NA	NA
List of analyses
Baseline characteristics (table 3)	X	X	X
Infection by CTCAE Grade (table 4)	X	X
AEs leading to d/c (table 5)	X	X	X
Neutrophils and lymphocytes over time (figure 1)				X	X
Platelets over time (figure 2)				X	X
Change in haemoglobin over time (figure 3)				X	X
Reversibility (figures 1B, D and 2B)	X	X
Neutrophils by hsCRP (online supplemental figure 1)						X
Platelets over time by baseline platelet quartile (online supplemental figure 2)							X
Mean platelet count and volume (online supplemental figure 3)						X
Thrombocytosis by DVT/PE or no (online supplemental figure 4)			X
Baseline haemoglobin by hsCRP cat., gender, and age (online supplemental figure 5)								X
Haemogloblin over time by baseline hsCRP quartile (online supplemental figure 6)				X (Bari 4 mg only)
Change in erythropoetin, reticulocytes and RBC over time (online supplemental figure 7)									X
Change in total iron-binding capacity (online supplemental figure 8)									X
Platelet count shift (online supplemental table 1)	X	X
Baseline anaemia by prior medications (online supplemental table 2)								X

* Data for the follow-up period after treatment discontinuation are included in this analysis.
AEs, adverse events; Bari, baricitinib; cat., category; CTCAE, Common Terminology Criteria for Adverse Events; DVT/PE, deep vein thrombosis/pulmonary embolism; hsCRP, high-sensitivity C reactive protein, LTE, long-term extension (JADY study); NA, not applicable; RA, rheumatoid arthritis; RBC, red blood cell.